A new method to detoxify the inner ear from harmful drugs
A novel nanodialysis platform for inner ear detoxification
This study is testing a new gel that can help protect your hearing while you receive chemotherapy, making it safer and more comfortable for you by reducing the harmful effects of a common cancer drug.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10675694 on NIH RePORTER |
What this research studies
This research focuses on developing a novel hydrogel-based delivery system that can safely and effectively detoxify the inner ear from the harmful effects of Cisplatin, a common chemotherapy drug known to cause hearing loss. The approach involves applying a hydrogel to the round window membrane of the ear, allowing for controlled release of therapeutic agents to counteract drug-induced ototoxicity. The system includes an enzymatic 'off-switch' to stop drug delivery when necessary, enhancing patient safety and comfort. This outpatient procedure aims to improve the quality of life for patients undergoing chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving Cisplatin chemotherapy and are at risk of developing hearing loss.
Not a fit: Patients who are not undergoing Cisplatin treatment or those with pre-existing severe hearing loss may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce hearing loss in cancer patients treated with Cisplatin, improving their overall quality of life.
How similar studies have performed: Other research has shown promise in using nanotechnology for drug delivery and detoxification, suggesting that this approach could be effective.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Li, Daqing — University of Pennsylvania
- Study coordinator: Li, Daqing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.